8-K: Nutex Health Q3 Growth, Nasdaq Compliance Deadline

Nutex Health Inc. reported significant year-over-year growth in patient volume and cash collections for Q3 2025, while also addressing Nasdaq non-compliance due to delayed financial filings and restatement of prior financials.

Summary

• Preliminary estimated patient volume for Q3 2025 increased 11.1% year-over-year to 46,293 visits.
• Preliminary estimated cash collections for Q3 2025 surged 258.8% year-over-year to $235,003 thousand.
• Year-to-date 2025 estimated patient volume increased 14.0% to 140,135 visits.
• Year-to-date 2025 estimated cash collections grew 176.9% to $546,003 thousand.
• Received a Nasdaq notice on August 20, 2025, for non-compliance with Listing Rule 5250(c)(1) due to the failure to timely file the Quarterly Report on Form 10-Q for the period ended June 30, 2025.
• Submitted a plan to Nasdaq on October 15, 2025, to regain compliance and was granted an extension until December 12, 2025, to file the delinquent June 30, 2025 Form 10-Q.
• Previously issued financial statements for Q1 2025 (Form 10-Q) and FY 2024 (Form 10-K) should no longer be relied upon due to identified errors in accounting for certain non-cash obligations related to earn-out arrangements from the April 1, 2022 merger.
• Anticipates filing the delinquent June 30, 2025 Form 10-Q and the September 30, 2025 Form 10-Q no later than the December 12, 2025 deadline.

Sentiment

Score: 3

Explanation: While the company reported strong preliminary operational growth, the significant issues with financial reporting, the need to restate previous financials, and the Nasdaq non-compliance notice with a delisting threat create substantial uncertainty and risk for investors, overshadowing the positive operational metrics.

Positives

• Q3 2025 estimated patient volume increased 11.1% year-over-year to 46,293, supported by strategic facility expansion and increased demand.
• Q3 2025 estimated cash collections surged 258.8% year-over-year to $235,003 thousand, indicating enhanced revenue cycle management, payer mix, and higher patient acuity.
• Year-to-date 2025 estimated patient volume increased 14.0% to 140,135.
• Year-to-date 2025 estimated cash collections grew 176.9% to $546,003 thousand.
• Nasdaq granted an extension until December 12, 2025, to file the delinquent Q2 2025 Form 10-Q, providing a pathway to regain compliance.

Negatives

• Failure to timely file the Quarterly Report on Form 10-Q for the period ended June 30, 2025, resulted in a Nasdaq non-compliance notice.
• Previously issued financial statements for Q1 2025 and FY 2024 should no longer be relied upon due to identified accounting errors related to earn-out arrangements from the April 1, 2022 merger.
• Risk of delisting from Nasdaq if the June 30, 2025 Form 10-Q is not filed with the SEC on or before December 12, 2025.
• The Q3 2025 Form 10-Q is anticipated to be filed later than its due date, as it depends on the sequential completion and filing of the restated and delayed reports.

Risks

• Inability to successfully execute growth strategy.
• Failure to finalize required amendments to and delinquent SEC filings within the anticipated timeframe.
• Inability to remediate the newly identified material weakness in internal control over financial reporting in a timely manner.
• Changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act.
• Economic conditions affecting healthcare demand and operations.
• Dependence on management and potential for dilution to stockholders.
• Lack of capital and ability to obtain future financing.
• Effects of rapid growth upon the company and management's ability to effectively respond.
• Challenges from newly developing technologies and the company's ability to compete.
• Conflicts of interest in related party transactions.
• Regulatory matters and protection of technology.
• Lack of industry standards and effects of competition.
• Potential delisting from Nasdaq if compliance is not regained by December 12, 2025.

Future Outlook

The company anticipates filing its delinquent Form 10-Q for the period ended June 30, 2025, and its Form 10-Q for the period ended September 30, 2025, no later than the December 12, 2025, deadline specified in the Nasdaq Exception Notice. It is committed to meeting all ongoing Nasdaq listing standards and is working diligently to complete and file all periodic reports.

Management Comments

• "Nutex is committed to meeting all ongoing requirements of Nasdaq's listing standards and is working diligently to complete and file its delinquent Form 10-Q, as well as all subsequent periodic reports."
• "We anticipate filing our delinquent Form 10-Q for the period ended June 30, 2025 and our Form 10-Q for the period ended September 30, 2025 no later than the deadline specified in the Nasdaq Exception Notice."

Industry Context

Nutex Health operates in the integrated healthcare delivery system, specifically with micro-hospitals and population health management. The reported growth in patient volume and cash collections suggests strong demand for community-based acute care services, aligning with a broader trend towards localized and accessible healthcare. However, the significant financial reporting issues and compliance challenges highlight the complexities of managing accounting for mergers and acquisitions, a common hurdle in a consolidating healthcare industry.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing to allow for a direct comparison to global benchmarks or industry peers.

Corporate Governance

Stakeholder Impact

• Shareholders face uncertainty regarding the accuracy of past financial statements, potential share price volatility due to compliance issues and delisting risk, and potential dilution risk if future financing is required.
• Regulators (SEC, Nasdaq) will maintain increased scrutiny due to non-compliance and financial reporting errors.
• Creditors/Lenders may face increased risk perception due to financial reporting unreliability and compliance issues.

Next Steps

• Complete the preparation of financial statements for Q3 2025.
• Complete the restatement of previously issued financial statements (Q1 2025 10-Q and FY 2024 10-K).
• File the delinquent Form 10-Q for the period ended June 30, 2025, by December 12, 2025.
• File the Form 10-Q for the period ended September 30, 2025, by December 12, 2025.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Recommendation

Despite strong preliminary operational metrics, the severe financial reporting issues, including the need to restate prior financials and the Nasdaq non-compliance notice with a delisting deadline, create significant uncertainty and risk. The lack of reliable historical financial data and the potential for delisting make the stock highly speculative and warrant a cautious approach, suggesting a sell recommendation until these fundamental issues are resolved and financial transparency is restored.

Keywords

Nutex Health, NUTX, SEC filing, 8-K, Q3 2025, financial results, patient volume, cash collections, Nasdaq compliance, delisting risk, financial restatement, healthcare, micro-hospitals, population health management, earn-out arrangements, financial reporting errors